iso-stigmasteryl methyl ether | 10453-25-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: iso-stigmasteryl methyl ether
• 英文别名: i-stigmasteryl methyl ether；stigmasterol methyl ether；3β-methoxy-stigmasta-5,22t-diene；3β-Methoxy-stigmasta-5,22t-dien；Stigmasterylmethylether；(3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene
• CAS: 10453-25-5
• 化学式: C₃₀H₅₀O
• 分子量: 426.726
• InChiKey: WAIQWYALYSCYLA-LVVYUBKHSA-N

物化性质

• 熔点：
  121 °C
• 沸点：
  490.7±24.0 °C(Predicted)
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  9.1
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  iso-stigmasteryl methyl ether 在 palladium 10% on activated carbon 、 zinc diacetate 、 氢气 、 potassium hydroxide 作用下， 以 甲醇 、 乙醚 、 乙醇 为溶剂， 反应 17.0h， 生成 植物甾醇
  参考文献：
  名称：

  使用豆甾醇合成 1α-羟基维生素 D5 和相关化合物的功能性中间体的实用简便途径

  摘要：

  As a functional and versatile intermediate for the synthesis of la-hydroxyvitamin D-5 and related compounds, 1 alpha,2 alpha-epoxy-3 beta-hydroxystigmasta-5,7-diene was synthesized by a practical and facile 17-step route from stigmasterol in 17% overall yield.

  DOI：

  10.3987/com-15-s(t)6
• 作为产物：
  描述：

  豆甾醇 在 吡啶 、 potassium acetate 作用下， 反应 26.0h， 生成 iso-stigmasteryl methyl ether
  参考文献：
  名称：

  使用豆甾醇合成 1α-羟基维生素 D5 和相关化合物的功能性中间体的实用简便途径

  摘要：

  As a functional and versatile intermediate for the synthesis of la-hydroxyvitamin D-5 and related compounds, 1 alpha,2 alpha-epoxy-3 beta-hydroxystigmasta-5,7-diene was synthesized by a practical and facile 17-step route from stigmasterol in 17% overall yield.

  DOI：

  10.3987/com-15-s(t)6

文献信息

• Nurotoxic sterol glycosides
  申请人：Shaw Christopher Ariel

  公开号：US09573972B2

  公开（公告）日：2017-02-21

  The invention relates to compositions for use in animal models of neurodegenerative disease and methods therefor. More particularly, the invention relates to the use of neurotoxic sterol glycosides or neurotoxic glycolipids, or combinations thereof, in animal models of neurodegenerative disease. Neurotoxicity-modulating chromenols can also be used in these animal models in combination with the neurotoxic sterol glycosides or neurotoxic glycolipids, or combinations thereof.

  这项发明涉及用于神经退行性疾病动物模型的组合物和相应的方法。更具体地，该发明涉及在神经退行性疾病动物模型中使用神经毒性甾醇糖苷或神经毒性糖脂，或二者的组合。神经毒性调节色酚类化合物也可以与神经毒性甾醇糖苷或神经毒性糖脂，或二者的组合一起在这些动物模型中使用。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME
  申请人：Kandula Mahesh

  公开号：US20150080345A1

  公开（公告）日：2015-03-19

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. such compositions may be used to treatment of fasting hyperglycemia, diabetes mellitus type 2, impaired fasting glucose, impaired glucose tolerance, or insulin resistance, high blood pressure, central obesity (also known as visceral, male-pattern or apple-shaped adiposity), overweight with fat deposits mainly around the waist, decreased HDL cholesterol, elevated triglycerides, hyperuricemia, fatty liver (especially in concurrent obesity) progressing to NAFLD, polycystic ovarian syndrome (in women), hypophosphatemia, renal diseases, albuminuria, end stage renal disease, and acanthosis nigricans.

  本发明涉及化学式I和化学式II的化合物或其药学上可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括化学式I或化学式II化合物的有效量的药物组合物，以及用于治疗、预防或调节代谢综合征的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道、糖浆或注射剂的制剂。这些组合物可以用于治疗空腹高血糖、2型糖尿病、空腹血糖受损、糖耐量受损或胰岛素抵抗、高血压、中心性肥胖（也称为内脏、男性型或苹果形脂肪）、腰部脂肪沉积较多的超重、HDL胆固醇降低、甘油三酯升高、高尿酸血症、脂肪肝（尤其是伴有肥胖的进展到NAFLD）、多囊卵巢综合征（女性）、低磷血症、肾脏疾病、蛋白尿、晚期肾脏疾病和棕色糠疹。
• Synthesis, isolation and characterisation of β-sitosterol and β-sitosterol oxide derivatives
  作者：Florence O. McCarthy、Jay Chopra、Alan Ford、Sean A. Hogan、Joe P. Kerry、Nora M. O'Brien、Eileen Ryan、Anita R. Maguire

  DOI：10.1039/b505069c

  日期：——

  β-Sitosterol is the most prevalent plant cholesterol derivative (phytosterol) and can undergo similar oxidation to cholesterol, leading to β-sitosterol oxides. The biological impact of phytosterol oxides has only been evaluated in a phytosterol blend (usually of β-sitosterol, campesterol, stigmasterol and dihydrobrassicasterol). The lack of pure phytosterols, including β-sitosterol, hinders the collection of significant toxicity data on the individual β-sitosterol oxides. An efficient synthetic route to multi-gram quantities of pure β-sitosterol is described here, together with the first syntheses and characterisation of pure β-sitosterol oxides.

  δ-谷甾醇是最常见的植物胆固醇衍生物（植物甾醇），可发生与胆固醇类似的氧化作用，生成δ-谷甾醇氧化物。植物固醇氧化物的生物影响只在植物固醇混合物（通常包括δ-谷甾醇、坎贝酯醇、豆甾醇和二氢巴西甾醇）中进行过评估。由于缺乏纯植物甾醇（包括δ-谷甾醇），因此无法收集有关单个δ-谷甾醇氧化物的重要毒性数据。本文介绍了多克纯δ-谷甾醇的高效合成路线，以及纯δ-谷甾醇氧化物的首次合成和表征。
• Synthesis and Characterization of Stigmasterol Oxidation Products
  作者：David A. Foley、Yvonne O’Callaghan、Nora M. O’Brien、Florence O. McCarthy、Anita R. Maguire

  DOI：10.1021/jf9024745

  日期：2010.1.27

  The synthesis and structural characterization of a series of oxides of stigmasterol is described providing a valuable series of reference standards for these oxides, analogous to the cholesterol oxidation products (COPs) which have been shown to have detrimental biological effects. Biological evaluation of the oxides of phytosterols is significant in the context of increased dietary use of phytosterols

  描述了一系列豆甾醇的氧化物的合成和结构表征，为这些氧化物提供了一系列有价值的参考标准，类似于已证明具有有害生物作用的胆固醇氧化产物（COP）。在饮食中增加植物甾醇的使用以降低胆固醇吸收的情况下，对植物甾醇的氧化物的生物学评估是重要的。
• FORMULATIONS OF LIPOPHILIC BIOACTIVE MOLECULES
  申请人：Zumes, LLC

  公开号：US20140039052A1

  公开（公告）日：2014-02-06

  This invention provides aqueous and non-aqueous clear formulations including at least one lipophilic bioactive molecules and an amphiphilic solubilizing agent. Exemplary aqueous formulations include a water-soluble reducing agent, which diminishes or prevents chemical degradation of the lipophilic bioactive molecule. The invention also provides methods of using the formulations of the invention. For example, the invention provides beverages including the formulations of the invention. The invention further provides methods of making the formulations and beverages.

  本发明提供了包括至少一种亲脂性生物活性分子和一种两性溶解剂的水性和非水性透明配方。其中，水性配方包括水溶性还原剂，可减少或防止亲脂性生物活性分子的化学降解。本发明还提供了使用该配方的方法。例如，本发明提供了包括该配方的饮料。本发明还提供了制备该配方和饮料的方法。